Key result
Higher circulating full-length endotrophin is linked to increased CV and all-cause mortality in HFpEF.
Why the study?
Endotrophin has previously been quantified in circulation by the PRO-C6 assay, which detects various proteolytic fragments rather than exclusively full-length endotrophin.
Does elevated circulating full-length endotrophin predict all-cause and cardiovascular mortality in patients with HFpEF?
Cohort (n=218)
Yes
Does elevated circulating full-length endotrophin predict all-cause and cardiovascular mortality in patients with HFpEF?
A novel immunoassay for full-length endotrophin demonstrates that elevated circulating levels are independently associated with increased all-cause and cardiovascular mortality in patients with HFpEF.
May aid HFpEF risk stratification; leaves open endotrophin’s clinical utility pending validation.
Endotrophin is a matrikine released from the C-terminus of the alpha-3 chain of type VI collagen, gaining increasing attention both as a biomarker and as a therapeutic target in the cardiometabolic space. So far, it has been quantified in circulation by the PRO-C6 assay, which detects different-sized proteolytic fragments of the C-terminus, including endotrophin. Here, we developed and evaluated a novel immunoassay targeting the full-length endotrophin, explored its biological relevance in two clinical cohorts of HFpEF, and investigated its potential as a prognostic biomarker. Increased circulating Endotrophin levels were associated with cardiovascular and all-cause mortality in both cohorts. When adjusting for relevant confounders, Endotrophin remained independently associated with both endpoints only in cohort 1. This work emphasizes the importance of the extracellular matrix in disease, confirms the prognostic value of endotrophin, and provides a novel tool for further exploration of its biological role.
No takes yet. Share an insight, caveat, or question.
Angeli et al. (2026) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=218). Full-length endotrophin biomarker assessment was evaluated on All-cause and cardiovascular mortality. Increased circulating full-length endotrophin levels were associated with cardiovascular and all-cause mortality in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: